|
|
|
Volumn 36, Issue 4 SUPPL. 8, 1999, Pages 26-32
|
|
The evolving role of oral topotecan
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DNA TOPOISOMERASE INHIBITOR;
ETOPOSIDE;
PLATINUM DERIVATIVE;
TAXANE DERIVATIVE;
TOPOTECAN;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
CONFERENCE PAPER;
DIARRHEA;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
HEMATOPOIETIC SYSTEM TUMOR;
HUMAN;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
NEUTROPENIA;
OVARY CANCER;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOLID TUMOR;
ADMINISTRATION, ORAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DNA TOPOISOMERASES, TYPE I;
FEMALE;
HUMANS;
MALE;
TOPOTECAN;
|
|
EID: 0033451685
PISSN: 00371963
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (13)
|
|
References (13)
|
